The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Current status and prospects of HIV treatment
Open accessAbstract
Current antiviral treatments can reduce HIV-associated morbidity, prolong survival, and prevent HIV transmission. Combination antiretroviral therapy (cART) containing preferably three active drugs from two or more classes is required for durable virologic suppression. Regimen selection is based on virologic efficacy, potential for adverse effects, pill burden and dosing frequency, drug-drug interaction potential, resistance test results, comorbid conditions, social status, and cost. With prolonged virologic suppression, improved clinical outcomes, and longer survival, patients will be exposed to antiretroviral agents for decades. Therefore, maximizing the safety and tolerability of cART is a high priority. Emergence of resistance and/or lack of tolerability in individual patients require availability of a range of treatment options. Development of new drugs is focused on improving safety (e.g. tenofovir alafenamide) and/or resistance profile (e.g. doravirine) within the existing drug classes, combination therapies with improved adherence (e.g. single-tablet regimens), novel mechanisms of action (e.g. attachment inhibitors, maturation inhibitors, broadly neutralizing antibodies), and treatment simplification with infrequent dosing (e.g. long-acting injectables). In parallel with cART innovations, research and development efforts focused on agents that target persistent HIV reservoirs may lead to prolonged drug-free remission and HIV cure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,405
Prevention of HIV-1 infection with early antiretroviral therapy.
Cohen, M. S., Chen, Y. Q., McCauley, M., Gamble, T., Hosseinipour, M. C., Kumarasamy, N., Hakim, J. G., Kumwenda, J., Grinsztejn, B., Pilotto, J. H. S., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105243 · Cited by 6,873
Guaraldi, G., Orlando, G., Zona, S., Menozzi, M., Carli, F., Garlassi, E., Berti, A., Rossi, E., Roverato, A., & Palella, F. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir627 · Cited by 1,331
Changing patterns of mortality across Europe in patients infected with HIV-1
Mocroft, A., Vella, S., Benfield, T., Chiesi, A., Miller, V, Gargalianos, P., Monforte, A. D., Yust, I., Bruun, J., Phillips, A., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03201-2 · Cited by 1,270
Estimated HIV Incidence in the United States, 2006–2009
Prejean, J., Song, R., Hernandez, A., Ziebell, R., Green, T., Walker, F., Lin, L. S., An, Q., Mermin, J., Lansky, A., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017502 · Cited by 1,071
Attia, S., Egger, M., Müller, M., Zwahlen, M., & Low, N. (2009) · AIDS · doi:10.1097/qad.0b013e32832b7dca · Cited by 1,001
Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
Walmsley, S. L., Antela, A., Clumeck, N., Duiculescu, D., Eberhard, A., Gutiérrez, F., Hocqueloux, L., Maggiolo, F., Sandkovsky, U., Granier, C., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215541 · Cited by 876
Montaner, J. S., Lima, V. D., Barrios, R., Yip, B., Wood, E., Kerr, T., Shannon, K., Harrigan, P. R., Hogg, R. S., Daly, P., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60936-1 · Cited by 780
Das, M., Chu, P. L., Santos, G.-M., Scheer, S., Vittinghoff, E., McFarland, W., & Colfax, G. N. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011068 · Cited by 771
Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117
Caskey, M., Klein, F., Lorenzi, J. C. C., Seaman, M. S., West, A. P., Buckley, N., Kremer, G., Nogueira, L., Braunschweig, M., Scheid, J. F., et al. (2015) · Nature · doi:10.1038/nature14411 · Cited by 767
Changes in Plasma HIV-1 RNA and CD4+ Lymphocyte Counts and the Risk of Progression to AIDS
O'Brien, W. A., Hartigan, P. M., Martin, D., Esinhart, J., Hill, A., Benoit, S., Rubin, M., Simberkoff, M. S., & Hamilton, J. D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602153340703 · Cited by 720
Sax, P. E., Wohl, D., Yin, M. T., Post, F., DeJesus, E., Saag, M., Pozniak, A., Thompson, M., Podzamczer, D., Molina, J. M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60616-x · Cited by 601
Self-citationMcComsey, G. A., Kitch, D., Daar, E. S., Tierney, C., Jahed, N. C., Tebas, P., Myers, L., Melbourne, K., Ha, B., & Sax, P. E. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir188 · Cited by 495
Lynch, R. M., Boritz, E., Coates, E. E., DeZure, A., Madden, P., Costner, P., Enama, M. E., Plummer, S., Holman, L., Hendel, C. S., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aad5752 · Cited by 465
Sax, P. E., DeJesus, E., Mills, A., Zolopa, A., Cohen, C., Wohl, D., Gallant, J. E., Liu, H. C., Zhong, L., Yale, K., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60917-9 · Cited by 444
Mocroft, A., Kirk, O., Reiss, P., De Wit, S., Sedlacek, D., Beniowski, M., Gatell, J., Phillips, A. N., Ledergerber, B., & Lundgren, J. D. (2010) · AIDS · doi:10.1097/qad.0b013e328339fe53 · Cited by 406
Lewden, C., Chêne, G., Morlat, P., Raffi, F., Dupon, M., Dellamonica, P., Pellegrin, J.-L., Katlama, C., Dabis, F., & Leport, C. (2007) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318134257a · Cited by 402
A Review of the Toxicity of HIV Medications
Margolis, A. M., Heverling, H., Pham, P. A., & Stolbach, A. (2014) · Journal of Medical Toxicology · doi:10.1007/s13181-013-0325-8 · Cited by 348
DeJesus, E., Rockstroh, J. K., Henry, K., Molina, J.-M., Gathe, J., Ramanathan, S., Wei, X., Yale, K., Szwarcberg, J., White, K., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60918-0 · Cited by 347
Daar, E. S., Tierney, C., Fischl, M. A., Sax, P. E., Mollan, K., Budhathoki, C., Godfrey, C., Jahed, N. C., Myers, L., Katzenstein, D., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-7-201104050-00316 · Cited by 312
Ruane, P. J., DeJesus, E., Berger, D., Markowitz, M., Bredeek, U. F., Callebaut, C., Zhong, L., Ramanathan, S., S. Rhee, M., Fordyce, M. W., et al. (2013) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3182965d45 · Cited by 302
Self-citationGenital HIV-1 RNA Predicts Risk of Heterosexual HIV-1 Transmission
Baeten, J. M., Kahle, E., Lingappa, J. R., Coombs, R. W., Delany-Moretlwe, S., Nakku-Joloba, E., Mugo, N. R., Wald, A., Corey, L., Donnell, D., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001888 · Cited by 293
Combination Antiretroviral Therapy and Recent Declines in AIDS Incidence and Mortality
Vittinghoff, E., Scheer, S., O'Malley, P., Colfax, G., Holmberg, S. D., & Buchbinder, S. P. (1999) · The Journal of Infectious Diseases · doi:10.1086/314623 · Cited by 275
Eradicating HIV-1 infection: seeking to clear a persistent pathogen
Archin, N. M., Sung, J. M., Garrido, C., Soriano-Sarabia, N., & Margolis, D. M. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3352 · Cited by 275
Trends in Diseases Reported on U.S. Death Certificates That Mentioned HIV Infection, 1987–1999
Selik, R. M., Byers, R. H., & Dworkin, M. S. (2002) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200204010-00009 · Cited by 239
HIV reservoirs as obstacles and opportunities for an HIV cure
Chun, T.-W., Moir, S., & Fauci, A. S. (2015) · Nature Immunology · doi:10.1038/ni.3152 · Cited by 232
Walmsley, S., Baumgarten, A., Berenguer, J., Felizarta, F., Florence, E., Khuong-Josses, M.-A., Kilby, J. M., Lutz, T., Podzamczer, D., Portilla, J., et al. (2015) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000790 · Cited by 227
Formulation and pharmacology of long-acting cabotegravir
Trezza, C., Ford, S. L., Spreen, W., Pan, R., & Piscitelli, S. (2015) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000168 · Cited by 179
Yamashita, T. E., Phair, J. P., Muñoz, A., Margolick, J. B., Detels, R., O'Brien, S. J., Mellors, J. W., Wolinsky, S. M., & Jacobson, L. P. (2001) · AIDS · doi:10.1097/00002030-200104130-00009 · Cited by 178
Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons
Choi, A. I., Vittinghoff, E., Deeks, S. G., Weekley, C. C., Li, Y., & Shlipak, M. G. (2011) · AIDS · doi:10.1097/qad.0b013e328347fa16 · Cited by 170
Obel, N., Farkas, D. K., Kronborg, G., Larsen, C. S., Pedersen, G., Riis, A. H., Pedersen, C. D., Gerstoft, J., & Sørensen, H. T. (2009) · HIV Medicine · doi:10.1111/j.1468-1293.2009.00751.x · Cited by 144
In Vitro Characterization of MK-1439, a Novel HIV-1 Nonnucleoside Reverse Transcriptase Inhibitor
Lai, M., Feng, M., Falgueyret, J., Tawa, P., Witmer, M. V., DiStefano, D. J., Li, Y., Burch, J. D., Sachs, N. A., Lu, M., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02403-13 · Cited by 143
Persistent HIV RNA shedding in semen despite effective antiretroviral therapy
Sheth, P. M., Kovacs, C., Kemal, K. S., Jones, R. B., Raboud, J., Pilon, R., la Porte, C., Ostrowski, M., Loutfy, M. R., Burger, H., et al. (2009) · AIDS · doi:10.1097/qad.0b013e3283303e04 · Cited by 140
Nowicka-Sans, B., Gong, Y.-F., McAuliffe, B. V., Dicker, I. B., Ho, H., Zhou, N., Eggers, B. J., Lin, P., Ray, N., Wind‐Rotolo, M., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00426-12 · Cited by 139
Initiation of antiretroviral therapy leads to a rapid decline in cervical and vaginal HIV-1 shedding
Graham, S. M., Holte, S. E., Peshu, N. M., Richardson, B. A., Panteleeff, D. D., Jaoko, W. G., Ndinya-Achola, J. O., Mandaliya, K. N., Overbaugh, J. M., & McClelland, R. S. (2007) · AIDS · doi:10.1097/qad.0b013e32801424bd · Cited by 136
Spreen, W. R., Min, S., Ford, S. L., Chen, S., Lou, Y., Bomar, M., Clair, M. S., Piscitelli, S., & Fujiwara, T. (2013) · HIV Clinical Trials · doi:10.1310/hct1405-192 · Cited by 114
Ford, S. L., Gould, E., Chen, S., Margolis, D., Spreen, W., Crauwels, H., & Piscitelli, S. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01235-13 · Cited by 83
Morlat, P., Vivot, A., Vandenhende, M. A., Dauchy, F., Asselineau, J., Deti, E., Gerard, Y., Lazaro, E., Duffau, P., Neau, D., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066223 · Cited by 66
Langley, D. R., Kimura, S. R., Sivaprakasam, P., Zhou, N., Dicker, I. B., McAuliffe, B. V., Wang, T., Kadow, J. F., Meanwell, N. A., & Krystal, M. (2014) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.24726 · Cited by 60
Cited by
Drug combinations: a strategy to extend the life of antibiotics in the 21st century
Tyers, M., & Wright, G. D. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0141-x · Cited by 820
Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing
Riva, L., Yuan, S., Yin, X., Martin-Sancho, L., Matsunaga, N., Pache, L., Burgstaller-Muehlbacher, S., De Jesus, P. D., Teriete, P., Hull, M. V., et al. (2020) · Nature · doi:10.1038/s41586-020-2577-1 · Cited by 760
QSAR-Based Virtual Screening: Advances and Applications in Drug Discovery
Neves, B. J., Braga, R. C., Melo-Filho, C. C., Moreira-Filho, J. T., Muratov, E. N., & Andrade, C. H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01275 · Cited by 494
Dopamine, Immunity, and Disease
Channer, B., Matt, S. M., Nickoloff-Bybel, E. A., Pappa, V., Agarwal, Y., Wickman, J., & Gaskill, P. J. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000618 · Cited by 308
Drug Combinations Against Soil-Transmitted Helminth Infections
(2019) · Advances in Parasitology · doi:10.1016/bs.apar.2018.08.002 · Cited by 92
Metadata
- Authors
- Cihlar, T., & Fordyce, M.
- Venue
- Current Opinion in Virology
- Publisher
- Elsevier BV
- Published
- 2016-06
- Volume
- 18
- Pages
- 50-56
- ISSN
- 1879-6257 (ISSN-L)
- OpenAlex
- W2315025523
- Cited by
- 337
- References
- 42
- FWCI
- 7.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.